Friedrich & ClementBETA

AOK Niedersachsen. Die Gesundheitskasse.

Germany · 296 open tenders · 12 documented awards

Current tenders

Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for medicinal products containing the active ingredient nadroparin (ATC code: B01AB06).
Deadline 27 Oct ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for medicinal products containing the active substance erythropoietin (ATC code B03XA01).
Deadline 27 Oct ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for medicinal products containing the active ingredient fondaparinux (ATC code: B01AX05).
Deadline 27 Oct ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for medicinal products with the active ingredient combination of brinzolamide and brimonidine (ATC code: S01EC24).
Deadline 27 Oct ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for medicinal products containing the active substance nadroparin (ATC code: B01AB06).
Deadline 27 Oct ·
Conclusion of a non-exclusive rebate agreement pursuant to § 130a (8) SGB V for medicinal products containing the active substance fondaparinux (ATC code: B01AX05).
Deadline 27 Oct ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for medicinal products containing the active ingredient erythropoietin (ATC code B03XA01).
Deadline 27 Oct ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for medicinal products with the active ingredient combination of brinzolamide and brimonidine (ATC code: S01EC24).
Deadline 27 Oct ·
Conclusion of a non-exclusive rebate agreement pursuant to § 130a para. 8 SGB V for medicinal products containing the active substance dimethyl fumarate (ATC code: L04AX07).
Deadline 27 Nov ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a (8) SGB V for medicinal products containing the active substance aripiprazole as depot injection suspension (ATC code: N05AX12).
Deadline 27 Nov ·
Conclusion of a non-exclusive rebate agreement pursuant to § 130a para. 8 SGB V for medicinal products containing the active substance pegfilgrastim (ATC code L03AA13).
Deadline 27 Nov ·
Conclusion of a non-exclusive rebate agreement pursuant to § 130a para. 8 SGB V for medicinal products with the active ingredient aripiprazole as depot injection suspension (ATC code: N05AX12).
Deadline 27 Nov ·
Conclusion of a non-exclusive rebate agreement pursuant to § 130a (8) SGB V for medicinal products containing the active substance pegfilgrastim (ATC code L03AA13).
Deadline 27 Nov ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for medicinal products containing the active substance dimethyl fumarate (ATC code: L04AX07).
Deadline 27 Nov ·
Conclusion of a non-exclusive rebate agreement pursuant to § 130a para. 8 SGB V for medicinal products containing the active substance mepolizumab (ATC code: R03DX09).
Deadline 28 Dec ·
Conclusion of a non-exclusive rebate agreement pursuant to § 130a (8) SGB V for medicinal products containing the active substance iron carboxymaltose (ATC code: B03AC01).
Deadline 28 Dec ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for medicinal products with the active ingredient combination of brinzolamide and timolol (ATC: S01ED67).
Deadline 28 Dec ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for medicinal products containing the active substance epinephrine (ATC code: C01CA24).
Deadline 28 Dec ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for medicinal products containing the active ingredient combination of brinzolamide and timolol (ATC: S01ED67).
Deadline 28 Dec ·
Conclusion of a non-exclusive rebate agreement pursuant to § 130a (8) SGB V for medicinal products containing the active substance epinephrine (ATC code: C01CA24).
Deadline 28 Dec ·
Conclusion of a non-exclusive rebate agreement pursuant to § 130a para. 8 SGB V for medicinal products containing the active ingredient iron carboxymaltose (ATC code: B03AC01).
Deadline 28 Dec ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for medicinal products containing the active ingredient mepolizumab (ATC code: R03DX09).
Deadline 28 Dec ·
Conclusion of a non-exclusive rebate agreement pursuant to § 130a para. 8 SGB V for medicinal products containing the active ingredient dornase alfa (ATC code R05CB13).
Deadline 25 Jan ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for medicinal products containing the active ingredient nitisinone (ATC code: A16AX04).
Deadline 25 Jan ·
Conclusion of a non-exclusive rebate agreement pursuant to § 130a para. 8 SGB V for medicinal products with the active ingredient combination of emtricitabine, rilpivirine and tenofovir disoproxil (ATC code J05AR08).
Deadline 25 Jan ·
Conclusion of a non-exclusive rebate agreement pursuant to § 130a para. 8 SGB V for medicinal products with the active ingredient Colecalciferol (A11CC05), excl. RX assortment.
Deadline 25 Jan ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for medicinal products containing the active ingredient sevelamer hydrochloride (ATC code V03AE02).
Deadline 25 Jan ·
Conclusion of a non-exclusive rebate agreement pursuant to § 130a (8) SGB V for medicinal products containing the active substance opipramol (ATC code: N06AA05).
Deadline 25 Jan ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for medicinal products containing the active ingredient amifampridine (ATC code: N07XX05).
Deadline 25 Jan ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for medicinal products containing the active ingredient Colecalciferol (A11CC05), excl. RX assortment.
Deadline 25 Jan ·

Purchasing rhythm

Awards per year — who knows the rhythm prepares before the notice appears.

2022109
2023107
2024157
2025141
2026106

Clement What the numbers say about this buyer

  • 27% of this buyer's awards went to companies that had already won here before (12 awards since 2022, spread over 9 companies). That is well below the national norm (45%) — this buyer switches suppliers more often than others.n = 12 awards since 2022
  • The median procedure drew just one bid (10 procedures with a bid count); 90% ended with a single bidder. Country: median 3.1 bids.n = 10
  • 8% of awards went to companies from abroad (12 awards with a known winner country). National average: 1%.n = 12

From this buyer's documented awards; comparison values from the same sector and country. Not a forecast, not legal advice. As of 04/10/2026.

Who has won here before

CompanyAwardsPeriod
Horn GmbH · Stutensee32025
DIGOTEX GmbH · Niederfischbach22026
Klinikverbund Landkreis Diepholz gGmbH12025
COMRAMO AG · Hannover12026
AbZ Pharma GmbH · Ulm12022
Binect GmbH · Weiterstadt12026
Stackfield GmbH · München12026
tde - trans data elektronik GmbH · Dortmund12024
amasol GmbH12026

From 18.0M documented awards · regular winners know this buyer's requirements — that is your competition.